UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register
Authors:
Open Access
- 10 October 2006
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 45 (11) , 1376-1379
Abstract
Objectives. The British Society for Rheumatology Biologics Register (BSRBR) is a prospective cohort study to determine the efficacy and toxicity of biological agents in rheumatoid arthritis (RA) patients compared with RA controls. Entry of patients to the register is a condition of use of anti-tumour necrosis factor (anti-TNF) therapy in the UK, but little is known of clinicians’ views of its usefulness. Data from the register suggest uneven provision of anti-TNF-α therapy. Methods. A questionnaire was sent on behalf of the BSRBR to all UK consultant rheumatologists concerning provision and use of anti-TNF-α therapy and their experience of working with the BSRBR. Results. Response rate was 49.5% representing 252 consultants. Fourty-six per cent had some limitation of access to anti-TNF-α drugs, usually a financial cap (70%), even for RA patients meeting National Institute for Health and Clinical Excellence (NICE) criteria. Sixty-seven per cent could prescribe for ankylosing spondylitis (AS) or psoriatic arthritis (PsA) in some circumstances but only 25 and 35%, respectively, could prescribe according to BSR guidance. More than 50% found the workload involved in submitting data to the registry at least difficult, but most had favourable impressions of the BSRBR and thought similar registries desirable or essential for PsA, AS and rituximab. Conclusions. Access to anti-TNF therapy for patients with inflammatory arthritis is variable in the UK, even for RA where it is NICE-approved. Access is more limited for conditions where NICE has not yet issued guidance. The BSRBR generates a significant workload for rheumatology staff but is generally well-regarded.Keywords
This publication has 21 references indexed in Scilit:
- Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trialArthritis & Rheumatism, 2006
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialAnnals of the Rheumatic Diseases, 2005
- Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitisArthritis & Rheumatism, 2003
- Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trialArthritis & Rheumatism, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000
- Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximabArthritis & Rheumatism, 2000
- Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFα treatmentAnnals of the Rheumatic Diseases, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999